Summary
Edwards Lifesciences Corporation (EW) reported its 2022 full-year results, demonstrating resilience despite prevailing macroeconomic challenges and the lingering effects of the COVID-19 pandemic. The company achieved net sales of $5.4 billion, a 2.9% increase year-over-year, driven primarily by strong performance in its Transcatheter Aortic Valve Replacement (TAVR) segment, which represented 65% of total net sales. The company continues to invest heavily in research and development, with R&D expenses increasing by 5% year-over-year, representing 18% of sales, focusing on next-generation TAVR technologies and expanding its Transcatheter Mitral and Tricuspid Therapies (TMTT) offerings. Despite foreign currency headwinds that impacted international sales by $140.2 million, Edwards Lifesciences maintained effective foreign currency hedging programs, contributing to a gross profit increase. The company also saw growth in its Surgical Structural Heart and Critical Care segments. Management highlighted key regulatory approvals and product launches in 2022, including FDA approval for the MITRIS RESILIA valve and PASCAL Precision system, and the launch of the SAPIEN 3 Ultra RESILIA valve in the U.S. While the company is navigating various risks, including regulatory compliance, competition, and supply chain considerations, its strategic focus on innovation and patient-centric solutions positions it for continued leadership in the structural heart disease and critical care monitoring markets.
Financial Highlights
54 data points| Revenue | $4.46B |
| Cost of Revenue | $723.70M |
| Gross Profit | $3.74B |
| R&D Expenses | $843.60M |
| SG&A Expenses | $1.36B |
| Operating Income | $1.50B |
| Interest Expense | $19.20M |
| Net Income | $1.52B |
| EPS (Basic) | $2.46 |
| EPS (Diluted) | $2.44 |
| Shares Outstanding (Basic) | 619.00M |
| Shares Outstanding (Diluted) | 624.20M |
Key Highlights
- 1Net sales for 2022 reached $5.4 billion, an increase of 2.9% compared to 2021, primarily driven by the TAVR segment.
- 2The company invested 17.6% of its net sales in R&D during 2022, signaling a strong commitment to innovation, particularly in TAVR and TMTT.
- 3Key product advancements in 2022 included FDA approval for the MITRIS RESILIA valve and PASCAL Precision system, and the U.S. launch of the SAPIEN 3 Ultra RESILIA valve.
- 4Despite foreign currency headwinds negatively impacting international sales by $140.2 million, the company's hedging programs helped offset some of these effects.
- 5The company repurchased $1.7 billion of its common stock in 2022, demonstrating a commitment to returning capital to shareholders.
- 6Operating income for 2022 was $1.75 billion, reflecting a slight increase from the prior year, despite increased SG&A and R&D expenses.